Inclusion Criteria:  A man or a woman, 18 years or older Willing and able to provide informed consent, or with a legal representative who can provide informed consent with participant's assent Has Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by an approved diagnostic test before randomization Currently hospitalized Documented increase in serum creatinine of 0.3 mg/dL or 50%-99% over baseline (baseline either based on admission serum creatinine or known pre-admission baseline, defined as most recent previous measurement) Participant or legal representative has read and signed the Informed Consent Form (ICF) after the nature of the study has been fully explained Is willing and able to provide authorization for the use and disclosure of personal health information in accordance with Health Insurance Portability and Accountability Act (HIPAA) Patients who are receiving remdesivir as a part of their clinical care or are in clinical trials of remdesivir or other antiviral drugs may be allowed if they meet other eligibility criteria Patients, who are participating in observational studies or studies of nonpharmacological interventions, will be allowed to participate Not be pregnant and not planning to become pregnant over the next 6 months  Exclusion Criteria:  In the intensive care unit at the time of screening or prior to randomization Requiring mechanical ventilation at the time of screening or prior to randomization Has baseline estimated glomerular filtration rate < 30 ml/min/1.73m2 Has a history of kidney transplantation or hemodialysis treatment or receiving or expected to receive hemodialysis or peritoneal dialysis at screening and prior to randomization Is on mechanical ventilation Has a contraindication for MIB-626 or its inert ingredients Has a diagnosis of lupus nephritis, polycystic kidney disease, other glomerular disease (other than diabetes) Has AST or ALT > 3 times the upper limit of normal Has other medical condition which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results Will exclude patients, who are receiving or are enrolled in placebo-controlled intervention trials of anti-inflammatory or immunomodulatory agents, such as tocilizumab. Occasional use of acetaminophen and nonsteroidal anti-inflammatory drugs, such as ibuprofen, for fever or headache is permitted.